Repligen Corporation - Product Pipeline Review - 2012 - This pharmaceuticals report, "Repligen Corporation - Product Pipeline Review - 2012" provides data on the Repligen Corporation's research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from our proprietary databases, Repligen Corporation's corporate website, SEC filings, investor presentations and featured press releases, both from Repligen Corporation and industry-specific third party sources, put together by This team.
Scope
- Repligen Corporation - Brief Repligen Corporation overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Repligen Corporation human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Repligen Corporation with complete description of the product's developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Repligen Corporation's pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.
Reasons to buy
- Evaluate Repligen Corporation's strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Repligen Corporation in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Repligen Corporation's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Repligen Corporation.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Repligen Corporation and identify potential opportunities in those areas.
Keywords
Current R&D Portfolio of Repligen Corporation; Repligen Corporation - Key Therapeutics; Repligen Corporation - Pipeline Overview and Promising Molecules; Repligen Corporation - News; Repligen Corporation - Latest Updates; Repligen Corporation - Pipeline; Repligen Corporation - Discontinued/Dormant Projects
Table of Contents
Table of Contents
List of Tables
List of Figures
Repligen Corporation Snapshot
Repligen Corporation Overview
Key Information
Key Facts
Repligen Corporation - Research and Development Overview
Key Therapeutic Areas
Repligen Corporation - Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products - Monotherapy
Repligen Corporation - Pipeline Products Glance
Repligen Corporation Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Repligen Corporation - Drug Profiles
RG2417
Product Description
Mechanism of Action
R&D Progress
RG2833
Product Description
Mechanism of Action
R&D Progress
RG3039
Product Description
Mechanism of Action
R&D Progress
Repligen Corporation - Pipeline Products by Route of Administration
Repligen Corporation - Pipeline Products By Mechanism of Action
Repligen Corporation - Recent Pipeline Updates
Repligen Corporation - Dormant Projects
Repligen Corporation - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
RG2133
Repligen Corporation - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Repligen Corporation, Recent Developments
Repligen Corporation- Press Release
Jun 22, 2012: Repligen Receives Complete Response Letter From FDA For RG1068 NDA
Apr 26, 2012: Repligen Provides Regulatory Update On RG1068 New Drug Application
Apr 25, 2012: Repligen Reports Positive Results From Phase I Clinical Trial Of RG3039 For Spinal Muscular Atrophy
Mar 23, 2012: Repligen Announces FDA Advisory Committee Date For SecreFlo New Drug Application
Mar 15, 2012: Repligen Initiates Phase I Clinical Trial Of RG2833 In Patients With Friedreich's Ataxia
Feb 21, 2012: Repligen Announces FDA Grant Of Priority Review For SecreFlo New Drug Application
Dec 09, 2009: Management Comments on Phase 3 Trial of RG1068 and Market Opportunities
Dec 09, 2009: Repligen Announces Phase 3 Clinical Trial Results Of RG1068 For Pancreatic Imaging
Financial Deals Landscape
Repligen Corporation, Deals Summary
Repligen Corporation, Pharmaceuticals & Healthcare, Deal Details
Asset Transactions
Repligen Acquires Chromatography Technology Platform From BioFlash Partners
Licensing Agreements
Repligen Enters Into Licensing Agreement With UCI
Repligen Enters Into Licensing Agreement With Families of Spinal Muscular Atrophy
Repligen Enters Into Licensing Agreement With McLean Hospital
Repligen Enters Into Licensing Agreement With Bristol-Myers Squibb
ImClone Systems Enters Into Licensing Agreement With Repligen
Repligen Enters Into Licensing Agreement With The Scripps Research Institute
Acquisition
Repligen Completes Acquisition Of Novozymes Biopharma For $29 Million
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Repligen Corporation, Key Information
Repligen Corporation, Key Facts
Repligen Corporation - Pipeline by Indication, 2012
Repligen Corporation - Pipeline by Stage of Development, 2012
Repligen Corporation - Monotherapy Products in Pipeline, 2012
Repligen Corporation - Phase II, 2012
Repligen Corporation - Phase I, 2012
Repligen Corporation - Pipeline By Route of Administration, 2012
Repligen Corporation - Pipeline Products By Mechanism of Action, 2012
Repligen Corporation - Recent Pipeline Updates, 2012
Repligen Corporation - Dormant Developmental Projects,2012
Repligen Corporation - Discontinued Pipeline Products, 2012
Repligen Corporation, Subsidiaries
Repligen Corporation, Deals Summary
Repligen Acquires Chromatography Technology Platform From BioFlash Partners
Repligen Enters Into Licensing Agreement With UCI
Repligen Enters Into Licensing Agreement With Families of Spinal Muscular Atrophy
Repligen Enters Into Licensing Agreement With McLean Hospital
Repligen Enters Into Licensing Agreement With Bristol-Myers Squibb
ImClone Systems Enters Into Licensing Agreement With Repligen
Repligen Enters Into Licensing Agreement With The Scripps Research Institute
Repligen Completes Acquisition Of Novozymes Biopharma For $29 Million
List of Figures
Repligen Corporation - Pipeline by Indication, 2012
Repligen Corporation - Pipeline by Stage of Development, 2012
Repligen Corporation - Monotherapy Products in Pipeline, 2012 9